Eli Lilly´s plans for 2023, five new types of drugs to launch

This year, tirzepatide received approval from U.S. health regulators and will be distributed under the brand

name Mounjaro. The other three drugs are mirikizumab to treat inflammatory bowel disease,

followed by lebrikizumab for atopic dermatitis and pirtobrutinib, which will help cure cancer.

Eli Lilly estimates the cost of marketing and related expenses at about $7 billion, up half a billion

from last year. Additional spending will be on research and drug improvement, amounting to

between $8.2 billion and $8.4 billion. The drugmaker estimates its 2023 revenues at $30.3 billion to

$30.8 billion, up from Wall Street's forecast of around $30.12 billion. The company plans to focus on

a different area of disease treatment, as last month the U.S. Food and Drug Administration took

away their authorization for bebtelovimab, an antibody covid-19 drug.

Obrázek1

Movement of Eli Lilly in the last five years. (Source: Trading Economics)

Sources:

estimates-2963196

Latest news